CytomX outlines registrational trial plans for Varseta-M in third-line colorectal cancer with initial study start in 2027

Varseta-M Phase I CRC data, response rates, safety and registrational trial plans for 2027—read key insights now.

CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer

Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W -- Estimated progression free survival of ...
Frontiers

Innovations in adoptive cell therapy: Overcoming safety and efficacy barriers through engineering, vaccination, and TME remodeling

Adoptive cell therapy (ACT) has emerged as a transformative approach in cancer immunotherapy, with remarkable clinical success in hematological ...